CXCL16 and neoplasm: Lysates of MTX-treated 9464D tumors displayed a more than 2.5-fold increase of IL1a, CXCL16, FLT3L, CX3CL1 and IL1RA, and a more than 1.5-fold increase of CXCL10, CXCL5, CCL5 and CXCL9 compared to control tumor lysates (Fig. 5E).